PROQR THERAPEUTICS EO-04 (0PQ) — Capital Reinvestment Ratio

Latest as of December 2023: 0.06x

PROQR THERAPEUTICS EO-04 (0PQ) has a Capital Reinvestment Ratio of 0.06x as of December 2023, meaning it reinvests 0% of its operating cash flow (€21.55 Million) in capital expenditures (€1.37 Million). Check PROQR THERAPEUTICS EO-04 (0PQ) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

€21.55 Million
EUR

Capital Expenditures

€1.37 Million
EUR

Data as of

Dec 2023
Most recent filing

PROQR THERAPEUTICS EO-04 Capital Reinvestment Ratio (2023–2023)

This chart tracks PROQR THERAPEUTICS EO-04's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see 0PQ cash flow conversion.

Annual Capital Reinvestment Ratio for PROQR THERAPEUTICS EO-04 (2023–2023)

Year-by-year Capital Reinvestment Ratio for PROQR THERAPEUTICS EO-04 from 2023 to 2023. See 0PQ FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2023 0.06x €21.55 Million €1.37 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow